Provided by Tiger Trade Technology Pte. Ltd.

Praxis Precision Medicines, Inc.

319.57
+13.954.56%
Post-market: 319.570.00000.00%19:53 EST
Volume:450.79K
Turnover:142.95M
Market Cap:8.76B
PE:-24.73
High:321.57
Open:310.84
Low:309.26
Close:305.62
52wk High:326.91
52wk Low:26.70
Shares:27.41M
Float Shares:22.92M
Volume Ratio:0.78
T/O Rate:1.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.9227
EPS(LYR):-10.2095
ROE:-75.20%
ROA:-45.09%
PB:25.50
PE(LYR):-31.30

Loading ...

Praxis Precision Medicines Grants Restricted Stock Units to New Employees Under 2024 Inducement Plan

Reuters
·
Feb 05

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Feb 05

Praxis Precision Med Is Maintained at Buy by Needham

Dow Jones
·
Feb 04

Needham Upside Case: Strong Ulixacaltamide Outlook and 2026 Catalyst Stack Drive Praxis Buy Thesis

TIPRANKS
·
Feb 04

Praxis Precision Med Initiated at Equal-Weight by Wells Fargo

Dow Jones
·
Feb 02

Wells Fargo Initiates Coverage on Praxis Precision Medicines With Equal Weight Rating, $282 Price Target

MT Newswires Live
·
Feb 02

Praxis Precision Med Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 31

Praxis Precision Medicines Inc : TD Cowen Raises Target Price to $554 From $353

THOMSON REUTERS
·
Jan 29

TD Cowen Remains a Buy on Praxis Precision Medicines (PRAX)

TIPRANKS
·
Jan 29

Praxis Precision Med Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Jan 28

Praxis Precision Medicines Appoints Dr. Orrin Devinsky as Head of Clinical Strategy

Reuters
·
Jan 14

Praxis Precision Medicines Appoints Global Epilepsy Leader DR. Orrin Devinsky as Head of Clinical Strategy

THOMSON REUTERS
·
Jan 14

Praxis Precision Medicines Inc. Files Initial Statement of Beneficial Ownership for Director Jeffrey B. Kindler

Reuters
·
Jan 13

Praxis Precision price target raised to $95 from $83 at Wedbush

TIPRANKS
·
Jan 12

Praxis Precision Med Is Maintained at Underperform by Wedbush

Dow Jones
·
Jan 12

Praxis Precision Medicines Highlights CNS Drug Pipeline and Commercial Strategy in New Presentation

Reuters
·
Jan 12

BRIEF-Praxis Precision Medicines Inc - Two NDA Submissions Expected By Mid-Feb 2026 For Ulixacaltamide In Essential Tremor & Relutrigine In Scn2a/8A-Dees

Reuters
·
Jan 12

Praxis Precision Medicines Inc - Two Nda Submissions Expected by Mid-Feb 2026 for Ulixacaltamide in Essential Tremor & Relutrigine in Scn2a/8a-Dees

THOMSON REUTERS
·
Jan 12

Praxis Precision Medicines Appoints Kinder and Arbuckle to Board and Promotes Sniecinski and Petrou to Leadership Roles

Reuters
·
Jan 12

Wedbush Raises Price Target on Praxis Precision Medicines to $95 From $83, Keeps Underperform Rating

MT Newswires Live
·
Jan 12